drugset / Trial / NCT07041437
Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Our study is aimed to evaluate the efficacy and safety of SHR-A2102 combined other antitumor treatments in advanced breast cancer.
Timeline
- Start
- 2025-06-30
- Primary completion
- 2026-09-30
- Completion
- 2027-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Subject | SHR-A2102 | Other / unclassified | — | — |